Literature DB >> 30165192

Smoothened stabilizes and protects TRAF6 from degradation: A novel non-canonical role of smoothened with implications in lymphoma biology.

Changju Qu1, Kranthi Kunkalla2, Amineh Vaghefi2, John K Frederiksen2, Yadong Liu1, Jennifer R Chapman2, Marzenna Blonska3, Leon Bernal-Mizrachi4, Juan Pablo Alderuccio3, Izidore S Lossos5, Ralf Landgraf6, Francisco Vega7.   

Abstract

Tumor necrosis factor receptor-associated factor 6 (TRAF6), an (K63) E3-ligase, plays a role in many biological processes and its activity is relevant in diffuse large B cell lymphoma (DLBCL) biology. Although molecules that trigger TRAF6 activation have been defined, those that stabilize TRAF6 and/or enhance TRAF6 function remain largely unclear. We found that TRAF6 amplifies pAKT signaling in DLBCL. Moreover, TRAF6 activation and stabilization of its ubiquitination profile are facilitated by smoothened (SMO), signal transducer of canonical Hedgehog signaling. Here, we report that SMO is needed to facilitate and maintain TRAF6-dependent elevated pAKT levels, and that the SMO/TRAF6 axis contributes to doxorubicin resistance in DLBCL. Mechanistically, we found that SMO, through its C-terminal tail, stabilizes and protects TRAF6 from degradation, an effect mediated by ubiquitin-specific protease-8. Moreover, this functional link between SMO and TRAF6 is reflected in DLBCL patients where high expression of both molecules correlates with poor prognosis. In summary, our study reveals a novel cell survival mechanism in which SMO stabilizes and protects TRAF6 from degradation. The axis SMO/TRAF6/AKT is highly relevant in the biology of DLBCL and is involved in doxorubicin resistance.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Diffuse large B cell lymphoma; Hedgehog signaling pathway; SMO; TRAF6

Mesh:

Substances:

Year:  2018        PMID: 30165192     DOI: 10.1016/j.canlet.2018.08.020

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  6 in total

1.  Resveratrol inhibits TRAF6/PTCH/SMO signal and regulates prostate cancer progression.

Authors:  Jianping Li; Ziming Wang; Hecheng Li; Jun Cao; Ning Nan; Xiaoqiang Zhai; Ying Liu; Tie Chong
Journal:  Cytotechnology       Date:  2022-09-07       Impact factor: 2.040

2.  PARK2 regulates eIF4B-driven lymphomagenesis.

Authors:  Bandish B Kapadia; Anirban Roychowdhury; Forum Kayastha; Nahid Nanaji; Ronald B Gartenhaus
Journal:  Mol Cancer Res       Date:  2022-02-01       Impact factor: 6.333

Review 3.  E3 Ubiquitin Ligase in Anticancer Drugdsla Resistance: Recent Advances and Future Potential.

Authors:  Yuanqi Liu; Chaojun Duan; Chunfang Zhang
Journal:  Front Pharmacol       Date:  2021-04-15       Impact factor: 5.810

Review 4.  Histone Modifications and Their Targeting in Lymphoid Malignancies.

Authors:  Miranda Fernández-Serrano; René Winkler; Juliana C Santos; Marguerite-Marie Le Pannérer; Marcus Buschbeck; Gaël Roué
Journal:  Int J Mol Sci       Date:  2021-12-27       Impact factor: 5.923

5.  Smoothened (SMO) regulates insulin-like growth factor 1 receptor (IGF1R) levels and protein kinase B (AKT) localization and signaling.

Authors:  Francisco Vega; Ralf Landgraf; Nitin K Agarwal; Chae-Hwa Kim; Kranthi Kunkalla; Amineh Vaghefi; Sandra Sanchez; Samantha Manuel; Daniel Bilbao
Journal:  Lab Invest       Date:  2021-12-10       Impact factor: 5.502

Review 6.  Role of K63-linked ubiquitination in cancer.

Authors:  Liangzi Cao; Xiaofang Liu; Bowen Zheng; Chengzhong Xing; Jingwei Liu
Journal:  Cell Death Discov       Date:  2022-10-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.